Cell Therapy Startup Funding 2025-2026

What are all the funding deals in the cell therapy market from July 2025 to June 2026?

The table below lists every disclosed equity round raised by pure-play cell therapy companies between July 2025 and June 2026. We define the cell therapy market as the market for cell-based medicinal products used as drugs to treat disease, including approved products and major late-stage pipeline therapies.

Each row shows the company, what it does, its category, the deal date, the funding stage, the round size, the region, the main investors, and the announcement source. For a wider view of how cell therapy fits inside the broader advanced therapies opportunity, we cover it in our Cell Therapy market report.

How active has fundraising been in the cell therapy market?

As of June 2026, fundraising in the cell therapy market has been active but uneven. Over the past 12 months, pure-play cell therapy companies raised 33 qualifying equity financings and $2.183B in disclosed capital.

The activity level is meaningful. The dataset averages 2.75 deals per month, with a median of 2.5 deals per month, which shows a steady flow of fundable companies.

The dollar picture is less smooth. Average capital raised per month was $181.9M, while the median was $116.4M, which means a few strong months pulled the average upward.

January 2026 was the clearest example. Four deals produced $595M that month, while February 2026 also had four deals but produced only $68.14M. Deal count alone does not explain the market.

If you want to go deeper on the companies behind these numbers, see our cell therapy market report.

How concentrated has fundraising been in the cell therapy market?

As of June 2026, fundraising in the cell therapy market has been highly concentrated. Over the past 12 months, the top 10 deals represented 68.1% of all disclosed capital.

The top 1 deal represented 11.5% of total capital, the top 3 reached 30.5%, and the top 5 reached 43.1%. This is a concentrated market, but not one dependent on a single financing.

The concentration pattern matters because the headline total of $2.183B can overstate breadth. A small cluster of late-stage, allogeneic, and platform financings drove a large share of the market.

Excluding rounds above $50M leaves $516.6M. That means the base layer of smaller and mid-sized financings is less than one quarter of the headline total.

How much of the cell therapy funding signal is driven by outliers?

As of June 2026, a large part of the cell therapy funding signal is driven by outliers. Over the past 12 months, 16 of 33 deals were $50M or larger, and 9 deals were above $100M.

The largest deal was Orca Bio at $250M, followed by Dispatch Bio at $216M and Allogene Therapeutics at $200.4M. These rounds materially shaped the overall capital picture.

Still, the outlier pattern is not extreme by biotech standards. The top deal held 11.5% of total capital, so the market was led by several large financings rather than one overwhelming event.

The right reading is that cell therapy funding is barbelled. Investors are funding large clinical or commercial milestones on one side, and differentiated early platforms on the other.

Is the cell therapy market broad with many targets, or narrow with few fundable companies?

As of June 2026, the cell therapy market is broader than a single-company story but still selective. Over the past 12 months, 33 qualifying equity financings came from 31 unique companies.

That unique-company count shows real breadth. Most companies in the dataset raised only once, which suggests the market is not merely recycling capital through a tiny set of repeat issuers.

At the same time, capital was selective. The top 10 deals captured 68.1% of dollars, so the funding pool favored companies with late-stage assets, platform credibility, or clear strategic validation.

Repeat financings also matter. Lyell Immunopharma and Oricell Therapeutics each appeared twice, showing that some companies can raise in layers when milestones or public-market windows align.

Is cell therapy mostly an early-stage formation market or a late-stage scaling market?

As of June 2026, the cell therapy market looks more like a late-stage scaling market than a pure early-stage formation market. Over the past 12 months, late-stage and growth rounds captured $1.396B, or 63.9% of total capital.

Early stage was still present, but it was not the dominant capital pool. Seed, Series A, and Series B rounds together raised $455.3M, equal to 20.9% of disclosed capital.

Unknown-stage financings added another $331.8M, or 15.2% of capital. That bucket matters because several platform or international rounds did not fit neatly into standard U.S. venture labels.

The stage data confirms a practical investor preference. Cell therapy companies close to pivotal trials, commercialization, IPO-readiness, or public-market credibility can still attract the largest checks.

For more context on how stage affects investor appetite, read our deeper analysis of the cell therapy market.

Which categories attract the most investor attention in cell therapy?

As of June 2026, CAR-T Therapies attracted the most investor attention in the cell therapy market. Over the past 12 months, CAR-T companies raised 13 of 33 deals and $646.3M.

That means CAR-T represented 39.4% of deal count and 29.6% of total capital. The category remained the most active, but its dollar share was smaller than its deal share.

Regenerative Cell Therapies ranked second by deal count, with 6 deals, while Allogeneic Cell Therapies ranked second by capital, with $510.9M. This split shows that attention and check size are not the same thing.

Engineered Immune Cells also remained visible, with 4 deals and $304M. The category benefited from solid-tumor and TCR-T interest, including larger platform-oriented financings.

Which categories attract disproportionately large checks in the cell therapy market?

As of June 2026, Late Stage Cell Therapies attracted the most disproportionately large checks in the cell therapy market. Over the past 12 months, the category represented only 6.1% of deals but 17.9% of capital.

The capital-share-to-deal-share ratio for Late Stage Cell Therapies was 2.95. That is the strongest ratio in the dataset and signals a major premium for near-commercial or late clinical execution.

Allogeneic Cell Therapies also attracted large checks. The category held 15.2% of deals and 23.4% of capital, with an average deal size of $102.2M and a median of $115M.

CAR-T was the most active category, but not the most oversized by check. Its capital-share-to-deal-share ratio was 0.75, which means many CAR-T rounds were mid-sized rather than universally large.

Which geographies matter most for fundraising in the cell therapy market?

As of June 2026, North America matters most for fundraising in the cell therapy market. Over the past 12 months, the region captured 19 deals and $1.573B, equal to 72.1% of total capital.

Asia-Pacific was the second major geography. It produced 11 deals and $537.94M, equal to 33.3% of deal count and 24.6% of disclosed capital.

Europe was present but much smaller. It produced 3 deals and $71.8M, equal to 9.1% of deals and only 3.3% of capital.

The geography split shows different capital roles. North America underwrote the largest platform, public-market, and late-stage financings, while Asia-Pacific provided a deeper but more fragmented set of rounds.

You can find a deeper geographic view in our market report on cell therapy fundraising.

Is the cell therapy opportunity set broad or concentrated in one hub?

As of June 2026, the cell therapy opportunity set is concentrated in a few hubs rather than spread globally. Over the past 12 months, North America and Asia-Pacific together held 96.7% of disclosed capital.

North America alone held 72.1% of capital and 57.6% of deals. That makes it the dominant hub for larger cell therapy financings.

Asia-Pacific was important on formation and deal count. Its 11 deals show a real market, especially across China, Japan, and Korea, but the region produced fewer very large checks.

Latin America, the Middle East, and Africa were absent from the qualifying dataset. That absence suggests cell therapy capital formation still depends heavily on regions with specialized clinical, manufacturing, and regulatory infrastructure.

Is cell therapy a market of small experiments or scaled financings?

As of June 2026, the cell therapy market is a market of scaled financings with a visible base of smaller rounds underneath. Over the past 12 months, 16 of 33 deals were $50M or larger.

The round-size distribution is top-heavy. There was 1 deal under $5M, 7 deals between $5M and under $20M, 9 deals between $20M and under $50M, and 16 deals at $50M or above.

The median round size was $48M, which is high for a technically complex therapeutic market. The average round size was $66.1M, pulled upward by the largest financings.

Rounds above $100M represented 9 deals, or 27.3% of all deals. That confirms investors are still willing to finance scaled cell therapy bets when the evidence, platform, or milestone is strong.

For a broader view of round sizes and category momentum, see our full market deck on cell therapy.

Who are the investors that appear the most in cell therapy fundraising?

As of June 2026, only a small number of investors appeared in more than one disclosed cell therapy financing. Over the past 12 months, the repeat-investor list was short and clustered around a few companies.

ARCH Venture Partners appeared in Dispatch Bio and CREATE Medicines. That pattern points to continued interest in next-generation immune-cell and in vivo cell therapy platforms.

Qiming Venture Partners and Beijing Medical and Health Care Industry Investment Fund appeared in Oricell Therapeutics’ January 2026 Series C1 and April 2026 pre-IPO financing. Those repeats reflect staged support around one company’s later private capital path.

RA Capital Management appeared in Azalea Therapeutics and Century Therapeutics. Lyell’s July 2025 private-placement investors also participated across both the July 2025 tranche and the March 2026 additional tranche.

One caveat is important. Round announcements disclose total financing size, but rarely disclose each investor’s individual check, so investor participation should not be read as investor-level dollars.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.